A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores

[1]  A. Mes-Masson,et al.  Analysis of active surveillance uptake for low-risk localized prostate cancer in Canada: a Canadian multi-institutional study , 2017, World Journal of Urology.

[2]  G. Sauter,et al.  Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins , 2017, World Journal of Urology.

[3]  M. Loda,et al.  Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. , 2016, European urology.

[4]  Javed Siddiqui,et al.  Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. , 2016, European urology.

[5]  S. Eggener.  Prostate Cancer Screening Biomarkers: An Emerging Embarrassment of 'Riches'? , 2016, European urology.

[6]  Pär Stattin,et al.  Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort. , 2016, European urology.

[7]  M. Rubin,et al.  Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer. , 2016, European urology.

[8]  Andrew P. Stubbs,et al.  Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential. , 2016, European urology.

[9]  C. Guillemette,et al.  The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression. , 2016, European urology.

[10]  A. Haese*,et al.  Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. , 2016, European urology.

[11]  L. Egevad,et al.  A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. , 2016, European urology.

[12]  F. Montorsi,et al.  Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. , 2016, European urology.

[13]  M. Cooperberg,et al.  Genomic Predictors of Outcome in Prostate Cancer. , 2015, European urology.

[14]  B. Delahunt,et al.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System , 2015, The American journal of surgical pathology.

[15]  J. Korbel,et al.  The aging prostate is never "normal": implications from the genomic characterization of multifocal prostate cancers. , 2015, European urology.

[16]  Nan Zhang,et al.  A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. , 2015, European urology.

[17]  M. Kattan,et al.  A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. , 2015, European urology.

[18]  Baris Turkbey,et al.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. , 2015, JAMA.

[19]  F. Montorsi,et al.  Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. , 2014, European urology.

[20]  L. Lessard,et al.  Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer. , 2013, European journal of cancer.

[21]  M. Kattan,et al.  Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. , 2010, European urology.

[22]  A. Haese*,et al.  Biochemical recurrence after radical prostatectomy: multiplicative interaction between surgical margin status and pathological stage. , 2010, The Journal of urology.

[23]  G. Sauter,et al.  Nuclear Grading Versus Gleason Grading in Small Samples Containing Prostate Cancer: A Tissue Microarray Study , 2010, Pathology & Oncology Research.

[24]  A. Haese*,et al.  Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. , 2010, European urology.

[25]  C. Le Page,et al.  Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-κB signalling pathway and prognostic significance in prostate cancer , 2010, British Journal of Cancer.

[26]  G. Sauter,et al.  Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. , 2009, European urology.

[27]  Pierre I Karakiewicz,et al.  Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. , 2009, The Journal of urology.

[28]  J. Diallo,et al.  Co‐assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis , 2008, BJU international.

[29]  F. Montorsi,et al.  A nomogram predicting long‐term biochemical recurrence after radical prostatectomy , 2008, Cancer.

[30]  A. Haese*,et al.  Development and external validation of an extended 10-core biopsy nomogram. , 2007, European urology.

[31]  K. Pienta,et al.  Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis , 2002, The American journal of surgical pathology.

[32]  H. Moch,et al.  Tissue microarray (TMA) technology: miniaturized pathology archives for high‐throughput in situ studies , 2001, The Journal of pathology.

[33]  B. Trock,et al.  Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. , 2016, European urology.